Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium

- Company to Host Conference Call on February 14 at 8:00 a.m. ET - CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Jan. 11, 2023-- Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that monotherapy dose escalation results of the ongoing Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, will be presented at the 2023 American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, being held February 16-18, 2023 in San Francisco, California. On Tuesday, February 14, 2023 at 8:00 a.m. ET, the Company will host a conference call with BT8009 investigator Dr. Capucine Baldini (Medical Oncologist, Gustave Roussy) and Dr. Daniel Petrylak (Professor of Medicine and Genitourinary Oncology, Yale School of Medicine) to discuss the data being presented. Poster Presentation Details Title: BT8009-100: A Phase I/II Study of a Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression, Including Urothelial Cancer Abstract #: 498 Presenter: Capucine Baldini, M.D., on behalf of the BT8009-100 investigators Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma Date/Time: Friday, February 17, 3:30 p.m. to 5:00 p.m.; 8:15 p.m. to 9:15 p.m. ET Conference Call Details Bicycle Therapeutics will host a conference call and webcast on Tuesday, February 14, 2023 at 8:00 a.m. ET to review the data being presented. To access the call, please dial (866) 652-5200 (domestic) or (412) 317-6060 (international) and provide the Conference ID 10174689. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com. About Bicycle Therapeutics Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005163/en/ Investors: David Borah, CFA SVP, Capital Markets & Corporate Communications [email protected] 617-203-8300 Media: Argot Partners Sarah Sutton [email protected] 212-600-1902 Source: Bicycle Therapeutics plc Press Releases Close IR Nav Overview →Stock Information →SEC Filings →Annual General Meeting →UK Annual Reports →Governance + Leadership →Presentation + Events →Analyst Coverage →Press Releases →Investor Resources → IR Nav Overview Stock Information SEC Filings Annual General Meeting UK Annual Reports Governance + Leadership Presentation + Events Analyst Coverage Press Releases Investor Resources United Kingdom Blocks A & B Portway Building Granta Park Great Abington Cambridge CB21 6GP View Google Map United States 4 Hartwell Place Lexington, MA 02421 View Google Map General Enquiries [email protected] Follow LinkedIn Twitter Privacy © Bicycle Therapeutics 2026 Designed by Greenspace Sign up Search Close Search Search → Hello We use cookies and other technologies to optimise your experience and analyse our traffic. Please confirm you are happy to accept. You can change your preferences in Cookie Settings. Find out more Accept var s_CCSWebHostingAccount = "trcgbicycle"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/9086","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb78741\/themes\/site\/nir_pid3307"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNkdFuQyEIhl-oOTbpxR6HoLLWHYUToNv69rW6pO2yZYsXCn7y8yMXBWSsFy_JAj9GC2aJBBXPnE47_hPcVPLAIhoNoiRhe065SI2oI5lWysVFIaP3FStZuB-XVxV24lmzoa7kg4RYJa1hyJuDohc-doVe8ITq_8INhsgvbCNkUErSWtfvD4Qfa5-rl9Zbx_AcjtsNj9Pp7bDgG34C5gypohlgJXX7gUvDqoNdOHUrzDRHtJV8OOxfgryTasmz4Q-KVpyApU-f5md8yy1f-866Z2rhNv8rJ2XCOg","theme":"nir_pid3307","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"364a63fdd1ba8bf28808b7d4a735dfbd500f3bdd6295cc883846cac82cce7d97"}}

The release as fetched from its publisher. bicycletherapeutics.com ↗